(^ Index)
(<– Previous session)

Talks in this session:

1. Choy: Intracellular trafficking and processing of amyloid precursor protein
2. Kown: Age-associated decline in immune function; new role of SIRT1 in regulatory T cells
3. Pan: Regulation of p53 and ageing by SnoN
4. Grueter: Disruption of the lipid synthesis gene, DGAT1, extends longevity

Regina Choy (Berkeley; Shekman lab) — Intracellular trafficking and processing of amyloid precursor protein

The talk began with a review of the proteolytic processing of amyloid precursor protein (APP) into Aß peptides. Choy emphasized that it is important to have a balance between the amyloidogenic and non-amyloidogenic pathways – a bias toward amyloidogenesis places one at risk for Alzheimer’s disease (AD).

The big question: Where is Aß being produced inside the cells? (What are the possible intracellular sites of Aß peptide production? Where is it actually happening). The approach: study of APP trafficking. The goal: Insights into regulation of Aß production and its relationship to AD.

Building on evidence that the primary site of Aß is the endosome, Choy performed RNAi knockdowns of the endosomal sorting machinery (ESCRT complexes as well as the ATPase VPS4). Knockdown of early components in endosomal sorting result in decreased Aß production, but knocking down the later components or VPS4 results in an increase in Aß production. Together with immunofluorescence results, these findings suggest that Aß production happens after APP leaves the early endosome. Surprisingly, however, APP does not colocalize with early endosome markers in the VPS4 knockdown – in fact, it ends up getting rerouted to the TGN. This raises the possibility that Aß production may happen after APP recycles through the TGN.

More beautiful immunofluorescence data followed, bolstering the recycling hypothesis and leading Choy to conclude in favor of a model in which the primary site of Aß production is in the TGN.

Hye-Sook Kown (Gladstone; Ott lab) — Age-associated decline in immune function; new role of SIRT1 in regulatory T cells

Regulatory T cells (Treg) maintain immune tolerance, i.e., they stop the rest of the immune system from attacking the body. They accomplish this by suppressing differentiation of naive cells and the activation of effector cells. This, in turn, helps to prevent autoimmune disease and graft rejection. However, Treg cells increase their activity during aging, which might make elderly people more susceptible to infection.

Treg activity is regulated by FoxP3, which is in turn modified by acetylation that is regulated by SIRT1. Kown used mass spec to identify the specific acetylation sites on FoxP3; she found three, and raising specific antibodies against the acetylated peptides.

Inhibition of SIRT1, a deacetylase, enhances acetylation of FoxP3 at a specific site in both Jurkat T cells and mouse inducible Treg (iTreg) cells. The acetylated protein is stabilized and active, promoting Treg differentiation and survival in a variety of cell culture and in vivo assays.

Thus, by downregulating the activity of Treg cells, SIRT1 promotes a more active immune system: lower iTreg activity promotes increased differentiation of naive T cells and activation of Th1, Th2 and Th17 effector cells. In older people where SIRT1 levels are lower, higher Treg activity may result in a less responsive immune system and higher susceptibility to infection.

In questions, I asked whether SIRT1 inhibition could therefore be used to prevent autoimmune disease – the short answer is “yes”; this has advantages over expanding Treg populations ex vivo, which sometimes results in loss of FoxP3 expression.

Deng Pan (Berkeley; Luo lab) — Regulation of p53 and ageing by SnoN

Starts off with a review of the cancer-aging hypothesis, i.e., the idea that the anticancer activity of tumor suppressors like p53 have a cost: apoptosis and senescence of damaged cells ultimately reduces the regenerative capacity of tissues, contributing to age-related decline in tissue function.

Pan has focused on SnoN, an inhibitor of TGFß/Smad signaling, using a knock-in mouse in which SnoN can no longer bind the Smad promoter. Using this system, he demonstrated that SnoN can function as a tumor suppressor by activating p53-dependent senescence.

SnoN can interact with the PML-p53 pathway; the SnoN protein is a component of PML-nuclear bodies, which in turn activate p53. There are several ways to activate p53: stabilization (i.e., preventing ubiquitination); antiprepression, and promoter-specific activation. How specifically is SnoN activating p53?

Using pulldown assays, Pan showed that SnoN can directly bind to p53, in a manner that does not depend on PML. This binding stabilizes p53, probably because SnoN competes with Mdm2 (which ubiquitinates p53, targeting it for destruction). The working model is that SnoN is a stress transducer that communicates information about cellular stress to the p53 pathway.

The knock-in mice showed premature aging-related phenotypes, including kyphosis and hair loss, as well as higher levels of senescent and apoptotic cells.

Carrie Grueter (Gladstone; Farese lab) — Disruption of the lipid synthesis gene, DGAT1, extends longevity

Given how much we know about fat and lifespan, it is perhaps surprising that very few longevity studies have focused on mice with modified lipid metabolism. To remedy this omission, Carrie Grueter has been studying the effect of the DGAT1 (diacylglycerol O-acyltransferase) knockout on phenotypes including lifespan. (DGAT is involved in triglyceride synthesis.)

Hypothesis: Leanness, with a concomitant improvement in metabolism, will extend longevity.

DGAT-deficient mice use more oxygen than wildtype siblings, but do not consume proportionally more food. The knockout mice are protected from the age-related increase in fat mass, as well as age-related increases in inflammation. (Not surprising since abdominal fat is associated with chronic inflammation.) The knockouts exhibit decreased serum IGF-I levels.

The payoff: DGAT knockouts live 25% longer than wildtype. There’s a cost: according to Grueter’s data, DGAT-KO have trouble lactating and therefore have decreased fecundity. Furthermore, the knockouts are bad at surviving short-term calorie restriction: half the mice fail to survive a 48-hour fast, probably because their core body temperatures plummet in the absence of stored fat to burn – the lethality can be rescued by group-housing the mice with wildtype animals or by raising the temperature to 30°C.

So in sum, the hypothesis enumerated above seems to hold, at least when calories are abundant – but when times are tough, it’s nice to have a little bit of extra padding.

(Next session –>)

Ouroboros

Animal studies support a cancer-promoting role for fat, and in humans, epidemiological data strongly suggest that dietary fat intake may be associated with incidence and mortality of cancers of the breast, colon, rectum, and prostate. There are also data implicating fat in cancers of the ovaries, uterus, pancreas, and lung, but the evidence is not as strong. There is still a debate as to whether it is total dietary fat, specific fats, or total calories that are involved in carcinogenesis. In any event, cancers of breast, colon, and prostate are highest in North America and western Europe and lowest in Asia, and are directly related to the intake of total fat in the diet even when adjusted for total calories. (more…)

The classical view of carcinogenesis was that it was a two-‘hit’ process – initiation (genetic) and promotion (epigenetic). However, this is too simplistic for definition of carcinogenesis and it is now realized that there may be six or more independent genetic mutational events. The newer theory of carcinogenesis is that it is a multistage process driven by both genetic damage (initiation) and other cellular changes (promotion). Tumor initiation begins in cells through genetic mutations that may be caused by chemical carcinogens, viruses, and physical agents. (more…)

Cancer Genetic Markers Of Susceptibility is based after populations in the NCI Cohort Range in addition to collaborative case-control epidemiologic reports by using biospecimens. Through scanning that DNA collected from men and women participating in these kinds of reports, may get determined handed down genetic versions associated with cancer tumor possibility that may bring about fresh preventive, analysis, in addition to restorative interventions. (more…)

The majority associated with leading cause of deaths in America are due to medical health issues, not accidents, regardless of what your mother told you. The National Center for Health Statistics compiles the listing of killers and leading causes of death in America. A number of on the list you can not manage but others you can. There are several things that you can do to minimize getting the risk of the leading causes of death. If you eat right, exercise, don’t smoke, keep your weight under control, and manage your stress, then you are having a big change to live longer and having prolonged life than average American. (more…)

Cancer occurrence rates in a period of time for a given population is expressed in various ways. The incidence rate is a direct measure of the probability of developing cancer and is usually expressed per year. Incidence rates may be crude (all ages) or age specific. Since cancer is very age dependent, age specific rates are usually more informative. Cancer in elderly is more prevalent compare to cancer in younger age. When comparing population groups with different age distributions (such as the United States vs. China), the incidence rate should be age adjusted by multiplying each age-specific rate by the percent of individuals in a population with the same ages and then summing these to produce a single value. For etiological studies, incidence rates tend to be more informative than mortality rates, as they identify all diagnosed cases. (more…)

Cancer is the second leading cause of mortality after heart disease and the leading cause of death among women ages 40 to 79 and men ages 60 to 79. Within the 65+ age group, the population 85 years and older is projected to double from 4.3 million in 2005 million by 2030. Life expectancy has increased. More people are treated successfully after a cancer diagnosis, resulting in a greater prevalence of the elderly living with or developing cancer. It is important for all professionals dealing with the elderly to understand what the disease is and how to deal with it. (more…)

Obesity in the elderly is a major health crisis facing our population that may predispose the elderly to the same adverse health outcomes facing the younger, obese population. However, several studies have suggested that the risk of obesity on life span is less in the elderly and may even become insignificant. However, these studies have found an increase in disability in older subjects with obesity. (more…)

The prevalence of sexual dysfunction in women approaches 43%, and age is an important correlate. The underlying etiology of sexual dysfunction in women is complex. Nevertheless, hormonal changes such as loss of estrogens and androgens contribute significantly to some of the sexual difficulties experienced by aging women. (more…)

Because it expresses my own orientation, I carry in my wallet a membership card to the Society for the Right to Die, which has imprinted on the back a signed statement of my living will.

When the aging process accelerates inexorably, you usually don’t just fail to wake up one morning because of old age. One of the many illnesses that afflict the elderly with increasing frequency will likely be the cause of death and dying. Here is where I feel a living will is important. (more…)